ClinicalTrials.gg
RecruitingNCT05699044ATTRABUpdated Jun 2, 2023

Screening of ATTRwt in Patient With Advanced AV-Block Undergoing Pacemaker Implantation

An observational study in Amyloid Cardiomyopathy and Block, AV, sponsored by Steen Hvitfeldt Poulsen. Recruiting at 1 site in Denmark. Open to participants aged 65 Years and older. Per ClinicalTrials.gov, last updated 2023-06-02.

Sponsored by Steen Hvitfeldt Poulsen · Observational

How we know

From the registry’s dates

  • Primary completion was expected by Aug 2025, 1 year 3 months ago, but the record still lists the study as recruiting.
  • Started Oct 2022; still recruiting 4 years 1 month later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
170
Ages
65 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 11 studies in Amyloid Neuropathies, Familial with a site in Denmark — 6 open to participants now, 7 under way, 2 of them phase 3. Amyloid Neuropathies, Familial · Denmark.

Started
2022
the only one that year
Observational
2 of 11
2 open now
Registered
5th of 11
by date
Lead sponsor
4 of 11
Steen Hvitfeldt Poulsen

Among the 11 studies in Amyloid Neuropathies, Familial with a site in Denmark, this one is the only one that started in 2022, is one of 2 observational ones, and was the 5th registered.

Amyloid Neuropathies, Familial

188 studies on the registry are indexed under Amyloid Neuropathies, Familial; 94 are open to participants now.

Browse Amyloid Neuropathies, Familial studies →

Open to participants now

6 of the 11 studies in Amyloid Neuropathies, Familial with a site in Denmark are open now. Recruiting first, the newest first:

All 6 open studies →

A study can be open while its sites in Denmark have not opened yet or have stopped. Only those recruiting at a site in Denmark →

Who these studies take

Of the 69 Amyloid Neuropathies, Familial studies recruiting now, 53 (77%) set no upper age limit and 1 (1%) stops at 75 or younger; 7 take children under 18; 9 take healthy volunteers.

This study: 65 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 11 studies in Amyloid Neuropathies, Familial with a site in Denmark, or all of them as a file.
02

Study summary

The investigators will nationally investigate the prevalence of Transthyretin Amyloidosis wildtype (ATTRwt) in patients of ≥ 65 years with left ventricular hypertrophy who present with high degree atrioventricular block (AV-block) and are admitted for pacemaker implantation. The investigators aim to characterize the group of patients with positive screening of ATTR and compare the ATTRwt disease stage at time of diagnosis for patients identified with ATTR at screening with a control group of routinely clinically diagnosed ATTRwt patients.

03

Conditions studied

  • Amyloid Cardiomyopathy
  • Block, AV
04

Who can participate

Ages eligible
65 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Probability sample

Study population

Patients admitted for pacemakerimplantation with advanced AV-block fulfilling eligibility criteria as described.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Men ≥65years or women ≥75years with unexplained AV-block with pacemaker indication, as decided per treating physician and presence of left ventricular hypertrophy ≥12mm.

Exclusion criteria

Exclusion Criteria:

  • Reversible causes for AV-block, som as AV-node disturbing medicament, ion-disturbances, hypothyroidism, hypoxia, ischemia, new heart surgery \<1month, endocarditis.
05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
170 participants (estimated)
Patient registry
No
Biospecimen retention
Samples without dna

Groups and cohorts

  • Amyloidosis Screening

    Patients fulfilling eligibility criteria will screened for Cardiac Amyloidosis.

    Diagnostic Test: Amyloidosis screening (bloodtest, DPD-scintigraphy, potentially endomyocardial biopsy)

Interventions

  • Diagnostic testAmyloidosis screening (bloodtest, DPD-scintigraphy, potentially endomyocardial biopsy)

    Bloodtest: Troponin I, NT-pro-BNP, electrolyte status, renal function, kampda/lambda free chain + ratio, M-komponent. DPD-scintigraphy. (Echocardiography)

06

What researchers measure

Primary outcomes

  1. Diagnosis of ATTRwt in study cohort.

    Number of participants with a diagnosis of ATTRwt in the study cohort based on DPD-scintigraphy or if necessary, a cardiac biopsy.

    Time frame: 3 years

Secondary outcomes

  1. Characteristics of patients with ATTRwt

    Echocardiographic (Left ventricular (LV) wall thickness, LV cavity dimension, EF, GLS, diastolic function, Right Ventricular (RV) systolic function, valve disease) Biochemical profile (Troponin I, NT-pro-BNP, Renal Function (E-GFR) ), presence or history of spinal stenosis, carpal tunnel syndrome

    Time frame: 3 years

  2. Clinical Stage of time of diagnosis in patients with ATTRwt

    Gilmore Staging

    Time frame: 3 years

  3. Number of heart-failure associated hospitalization among ATTRwt patients

    Time frame: 5 years

  4. All-cause mortality among ATTRwt patients.

    Time frame: 5 year

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Oct 2022 (actual). Primary completion is estimated for Aug 2025, 34 months after the start.

Of 74 observational studies under Amyloid Neuropathies, Familial, half reached primary completion within 65 months of starting (the median), counting those still running; a quarter within 30 and three quarters within 120. This study's planned 34 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 4, 2022
First posted
Jan 26, 2023
StartActual
Oct 1, 2022
Primary completionEst.
Aug 1, 2025
CompletionEst.
Oct 1, 2025
Last update
Jun 2, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 2, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05699044
Lead sponsor
Steen Hvitfeldt Poulsen
Responsible party
Steen Hvitfeldt Poulsen (Prof. Poulsen, Aarhus University Hospital Skejby) — Sponsor-investigator
First posted
Jan 26, 2023
Start date
Oct 1, 2022
Primary completion
Aug 1, 2025 (estimated)
Completion
Oct 1, 2025 (estimated)
Last update
Jun 2, 2023

Study contacts

Jens Skov, MD
Contact
jesmds@rm.dk
2074381 ext. +45
Steen Poulsen, MD
Contact
steenhvitfeldtpoulsen@gmail.com
30922309
Steen Poulsen, MD
principal investigator · Department of Cardiology, Aarhus University Hospital

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion